Why the Part B mark-up is a target for policymakers

Drug Pricing Lab
May 10, 2018

Policymakers are concerned that healthcare providers are influenced to prescribe more expensive drugs when they receive reimbursement based on the price plus a mark-up. The Drug Pricing Lab drew together published studies examining whether the 6% mark-up for administering drugs to Medicare Part B beneficiaries influences prescribing.  We find that all studies suggest it does, in just the direction policymakers are concerned about.

Download the report here.